Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Consensus Rating of “Moderate Buy” by Analysts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $246.0588.

Several research analysts have recently commented on the company. Sanford C. Bernstein reiterated a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday. Piper Sandler lifted their target price on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, May 22nd. TD Cowen lifted their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Wells Fargo & Company lifted their target price on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $245.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $236.17 on Friday. The firm has a market cap of $14.84 billion, a price-to-earnings ratio of -11,802.60, a PEG ratio of 0.21 and a beta of 0.32. The stock has a 50 day moving average of $216.77 and a 200-day moving average of $188.55. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals has a 52 week low of $105.00 and a 52 week high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. As a group, analysts forecast that Jazz Pharmaceuticals will post 22.09 EPS for the current year.

Insider Buying and Selling

In related news, Director Rick E. Winningham sold 2,741 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the sale, the director owned 9,567 shares of the company’s stock, valued at approximately $2,311,100.19. This trade represents a 22.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Heather Ann Mcsharry sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the sale, the director directly owned 18,449 shares in the company, valued at approximately $4,446,209. This trade represents a 9.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 10,741 shares of company stock valued at $2,287,143. Insiders own 4.30% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds have recently made changes to their positions in JAZZ. Vestal Point Capital LP bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth approximately $127,344,000. Goldentree Asset Management LP bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $149,597,000. Franklin Resources Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 164.0% in the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after purchasing an additional 1,129,995 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Jazz Pharmaceuticals by 160.2% in the 4th quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock worth $197,516,000 after purchasing an additional 715,361 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in shares of Jazz Pharmaceuticals by 258.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock worth $93,160,000 after purchasing an additional 395,000 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.